Company news
Invert Graphite Limited (ASX:IVG) news
Invert Graphite Limited news releases on 6ix. Latest, Oct 29, 2020: App 4C and Activities Report September 2020 Quarter
Press releases — page 2
App 4C and Activities Report September 2020 Quarter
October 28, 2020
Chair Address to AGM and LONGMILE presentation
July 29, 2020
Appendix 4D and Report for half-year to 30 June 2020
July 29, 2020
Continued Suspension from Official Quotation
July 24, 2020
Change to Board composition
July 23, 2020
FTT enters agreement- Veterinary Medical Technology Pipeline
July 23, 2020
Appendix 4C and Activities Report - June 2020 Quarter
July 22, 2020
Suspension from Official Quotation
July 17, 2020
Pause in Trading
July 15, 2020
Appendix 4C - quarterly cashflow and activities report
April 14, 2020
Board statement re Ramcap Ltd
April 3, 2020
Appendix 4E and Annual Report for year ended 31 December 19
February 19, 2020
Appendix 4C - December 2019 quarter
January 27, 2020
Appendix 4C and Shareholder Update
October 2, 2019
Appendix 4D and Half Year Report to 30 June 2019
August 8, 2019
Appendix 4C - June 2019 Quarter
July 12, 2019
Appendix 4C - March 2019 Quarter
April 23, 2019
Receipt of R&D tax rebate
March 22, 2019
Response to ASX Query
March 4, 2019
Annual Report for Financial Year to 31 Dec 2018
February 21, 2019
Placement completed to support future direction of Factor
February 4, 2019
Update regarding anticipated R&D tax incentive rebate
February 4, 2019
Appendix 4C - December quarter
January 30, 2019
Management Change
January 25, 2019
Results of Phase 2 Clinical Trial
November 13, 2018
Appendix 4C - September 2018 Quarter
October 19, 2018
Factor Therapeutics Appoints Transaction Advisor
October 15, 2018
Last patient completes treatment in VLU Ph 2 Clinical Trial
October 3, 2018
Half Yearly Report and Accounts
August 23, 2018
Appendix 4C - June 2018 quarter
July 27, 2018
Recruitment complete in VF00102 Phase 2 clinical trial
July 15, 2018
Screening to close as clinical trial nears completion
June 25, 2018
Clinical Trial Update
June 14, 2018
Receipt of $1.23M R&D tax incentive
May 15, 2018
Clinical trial update - recruitment enters final phase
May 13, 2018
Appendix 4C - March 2018 Quarter
April 26, 2018
Clinical Trial update - March quarter
April 9, 2018
Rights Issue Entitlement Offer Information Booklet
March 13, 2018
Appendix 4E Preliminary Final Report
February 22, 2018
Appendix 4C - December 2017 Quarter
January 25, 2018
Shareholder Update
January 14, 2018
Factor receives $3.1M R&D tax rebate
December 4, 2017
50% recruitment reached in VF00102 Clinical Trial
November 28, 2017
Appendix 4C for the September Quarter
October 29, 2017
Shareholder communication - clinical trial update
October 4, 2017
Appendix 4E and Full Year Statutory Accounts
August 14, 2017
Appendix 4C - quarterly
July 30, 2017
Appointment of Dr. Rosalind Wilson as CEO
May 21, 2017
Appendix 4C
April 26, 2017
Phase II clinical trial progress update
April 6, 2017